INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $70,820 | -27.0% | 86,366 | +38.8% | 0.00% | -60.0% |
| Q4 2022 | $97,034 | -23.6% | 62,201 | -15.5% | 0.01% | +25.0% |
| Q3 2022 | $127,000 | -2.3% | 73,597 | +1.7% | 0.00% | 0.0% |
| Q2 2022 | $130,000 | -44.2% | 72,362 | +13.4% | 0.00% | -20.0% |
| Q1 2022 | $233,000 | -29.4% | 63,817 | +0.4% | 0.01% | -28.6% |
| Q4 2021 | $330,000 | -40.9% | 63,584 | -17.2% | 0.01% | -30.0% |
| Q3 2021 | $558,000 | -4.5% | 76,809 | +24.4% | 0.01% | 0.0% |
| Q2 2021 | $584,000 | +4.1% | 61,764 | -3.0% | 0.01% | 0.0% |
| Q1 2021 | $561,000 | -24.4% | 63,673 | -22.7% | 0.01% | -37.5% |
| Q4 2020 | $742,000 | -38.7% | 82,399 | -23.0% | 0.02% | -57.9% |
| Q3 2020 | $1,211,000 | -38.4% | 107,051 | +72.6% | 0.04% | -45.7% |
| Q2 2020 | $1,965,000 | – | 62,020 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |